You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Two new studies of stage I to III CRC suggest that the presence of ctDNA in the months after surgery or chemotherapy can help identify patients who go on to relapse.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.
The analysis uncovered established subtypes and added new classifications, while also identifying a potential new treatment target.
Investigators showed that sequencing cell-free DNA could detect microsatellite instability, structural rearrangements, and clonal hematopoiesis in patients with metastatic disease.